Advanced Solid Tumors
Conditions
Brief summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of obrindatamab administered in combination with retifanlimab in patients with B7-H3- expressing tumors.
Detailed description
This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, PK, pharmacodynamics, immunogenicity, and preliminary antitumor activity of the combination of obrindatamab and retifanlimab, each of which is administered by IV infusion. The study consists of a Dose Escalation Phase to determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) (if no MTD is defined) of the combination, followed by a Cohort Expansion Phase to further define the safety and initial antitumor activity of the combination with the doses established in the Dose Escalation Phase. Patients with B7-H3-expressing unresectable, locally advanced, or metastatic solid tumors of any histology will be enrolled in the Dose Escalation Phase. Following the establishment of an MTD, additional patients with specific tumor types will enroll in the Cohort Expansion Phase.
Interventions
BIOLOGICALobrindatamab
B7-H3 x CD3 DART protein
BIOLOGICALretifanlimab
anti-PD-1 antibody
Sponsors
MacroGenics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
3+3+3 dose escalation design followed by Cohort Expansion Phase.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically-proven, unresectable locally advanced or metastatic solid tumors of any histology that test positive for B7-H3 expression on tumor cells or vasculature for whom no approved therapy with demonstrated clinical benefit is available. For all tumor types, the requirement for previous systemic therapy may be waived if a patient was intolerant of or refused standard first-line therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy ≥ 12 weeks * Measurable disease, with the exception of prostate cancer * Tissue specimen available for B7-H3 and PD-L1 expression testing * Acceptable laboratory parameters * Patients who have previously received an immune checkpoint inhibitor (e.g., anti- PD-L1, anti-PD-1, anti-CTLA-4) prior to enrollment must have toxicities related to the checkpoint inhibitor resolved to ≤ Grade 1 or baseline (prior to the checkpoint inhibitor) to be eligible for enrollment. Patients who experienced previous hypothyroidism toxicity on a checkpoint inhibitor are eligible to enter study regardless of Grade resolution as long as the patient is well controlled on thyroid replacement hormones.
Exclusion criteria
* Patients with history of prior central nervous system (CNS) metastasis must have been treated, must be asymptomatic, and must not have any of the following at the time of enrollment: 1. No concurrent treatment for the CNS disease (e.g. surgery, radiation, corticosteroids \>10 mg prednisone/day or equivalent) 2. No progression of CNS metastases on MRI or CT for at least 14 days after last day of prior therapy for the CNS metastases 3. No concurrent leptomeningeal disease or cord compression * Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past 2 years), and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing * Treatment with any, investigational therapy within the 4 weeks prior to the initiation of study drug administration * Treatment with any systemic chemotherapy within 3 weeks * Treatment with radiation therapy within 2 weeks * History of allogeneic bone marrow, stem-cell, or solid organ transplant * Treatment with systemic corticosteroids (\> 10 mg per day prednisone or equivalent) or other immune suppressive drugs within 2 weeks * Clinically significant cardiovascular or pulmonary disease * Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug. * Known history of positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome * Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 | 30 months | Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit. |
| MTD/MAD | 18 months | Maximum Tolerated or Administrated Dose of obrindatamab and retifanlimab |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tmax | 30 months | Time to reach maximum (peak) plasma concentration of obrindatamab and retifanlimab |
| Ctrough | 30 months | Trough plasma concentration of obrindatamab and retifanlimab |
| CL | 30 months | Total body clearance of the drug from plasma of obrindatamab and retifanlimab |
| AUC | 30 months | Area Under the Plasma Concentration versus Time Curve of obrindatamab and retifanlimab |
| t1/2 | 30 months | Terminal half life of obrindatamab and retifanlimab |
| ADA | 30 months | Percent of patients with anti-drug antibody to obrindatamab and retifanlimab |
| Anti-tumor activity | 30 months | Conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related response criteria (irRECIST) |
| Vss | 30 months | Apparent volume of distribution at steady state of obrindatamab and retifanlimab |
| Cmax | 30 months | Maximum Plasma Concentration of obrindatamab and retifanlimab |
Countries
United States
Outcome results
None listed